Physician profile
Jill Eileen Simpson
NPI 1295806701
$5,045.98
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $1,197 · 2023: $1,289 · 2024: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291 · Consulting Fee: $1,140 · Travel and Lodging: $53.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.70 |
| Consulting Fee | $1,140.00 |
| Travel and Lodging | $53.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,457.17 | 2022-2024 | Cimzia, Bimzelx |
| Amgen INC. | $772.39 | 2021-2024 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $510.21 | 2021-2024 | |
| Janssen Biotech, INC. | $481.45 | 2021-2024 | Tremfya |
| Lilly USA, LLC | $444.57 | 2022-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $274.60 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $209.48 | 2022-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $202.76 | 2021-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.66 | 2022-2024 | Ofev, Cyltezo |
| Pfizer INC. | $188.26 | 2021-2023 | |
| Glaxosmithkline, LLC. | $105.77 | 2022-2023 | Benlysta |
| Ani Pharmaceuticals, INC. | $44.85 | 2022 | |
| Aurinia Pharma U.S., INC. | $38.36 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.88 | 2024 | Orencia |
| Actelion Pharmaceuticals US, INC. | $22.68 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.35 | 2024 | Actemra |
| Hikma Pharmaceuticals USA | $20.87 | 2022 | |
| Fresenius Kabi USA, LLC | $18.82 | 2024 | Idacio |
| Celgene Corporation | $16.85 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.